Oxford Biomedica. 2005 to see 'Huge value creation' (Panmure Gordon)

Well Cantreme'is - we didn't exactly see a 'Milligan' (Spike) last time we marched up to 40p+ did we?

It is clear the immunotherapy sector has been targeted by the big boys seeing the huge success at Genentech and the weakness in their own product pipelines. There seems little doubt, from an M&A perspective, that things in this area will be seriously hotting-up over the coming months. The purchasing precedents and indeed valuations are now well set. Pharma must be running the slide rule over OXB at its current price, but critically, Alan DOES now have the cash, the question is does he also have the confidence of his investors to take this baby all the way - that's the billion $ ?, does OXB have the mgt clout, technical resource and bandwidth to manage, leverage and deliver its phenominal pipeline??? Questions questions...

Clear to all I'm sure now that shorters have long packed their bags and moved on (no surprise there) - further, we seem to have a sizeable buyer in the market. Great timing. IMHO we should now re-rate to 35p (or thereabouts) and in short order.

So I'd not be surprised at some sort of bid approach in the early NY. Target could be iro 45-50p. A hostile approach at this price would be hard for our new placement investors to turn down.......sadly. Though we shall have to wait and see.

Irrespective of that, it remains a great 'in' price sub 32p. Take full advantage/ IMHO...above all:-

WAIT!